MEDICINOVA INC
About MEDICINOVA INC
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $409.7K
- Net income
- -$12.0M
- Total assets
- $45.6M
- Market cap
- $64.5M
- Operating margin
- -3242.5%
- Net margin
- -2928.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $409.7K
- Operating expenses
- $13.7M
- Operating income
- -$13.3M
- Income tax
- $6.0K
- Net income
- -$12.0M
- EPS (basic)
- $-0.24
- EPS (diluted)
- $-0.24
Balance sheet
- Total assets
- $45.6M
- Current assets
- $31.0M
- Total liabilities
- $4.0M
- Current liabilities
- $3.8M
- Shareholders’ equity
- $41.6M
Cash flow
- Operating cash flow
- -$9.8M
- Investing cash flow
- -$2.9K
- Financing cash flow
- $244.0K
- Net cash flow
- -$9.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $64.5M
- EPS (diluted)
- $-0.24
- Shares outstanding
- 50.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 7, 2006
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $12.0M in FY2025.
- Trading 32% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MEDICINOVA INC.
Write a review
News about MEDICINOVA INC
News & sentiment via Polygon.io
